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both vaccine and placebo recipients. To investigate further, we dichotomized genotype as gB5 273 versus all other gB genotypes, then performed a linear regression of log10 viral load on genotype.
274
Around the time of seroconversion, a statistically significant association was found between log10 275 viral load and genotype, with the mean viral load in women with gB5 genotype viruses being 3.44 276 times greater than that of women shedding non-gB5 genotype viruses (95% CI 1.13-10.51, 277 p=0.031). When considering all visits, this association was no longer statistically significant; Despite the partial efficacy demonstrated by gB/MF59 vaccination in multiple clinical trials 282 (5) (6) (7) , there has been little examination of the impact of this vaccine on the in vivo viral populations.
283
In this investigation, we sought to employ the enhanced sensitivity of next-generation sequencing 284 (NGS) technology to delve deeper into the question of whether there are discernable differences 285 between viruses acquired by gB/MF59 vaccinees and placebo recipients. The advantage of NGS 286 over more traditional sequencing methodologies is the ability to detect minor viral variants, which 287 contribute to the diversity of the overall viral population (Figure 3 , Figure S4 ). We discovered that 288 numerous minor viral haplotypes, exceeding the threshold of PCR and sequencing error, were 289 detectable in nearly all clinical samples tested, which is consistent with results of HCMV whole-290 genome sequencing that have suggested numerous genetic variants at <1% frequency in the viral 291 population (11) (12) (13) . Interestingly, seropositive women reliably had more gB haplotypes ( Figure   292 1E) than acutely-infected vaccinated subjects, indicating a higher number of genetically-distinct 293 viral variants in seropositive, chronically HCMV-infected individuals. This observation 294 complements previous work demonstrating that recently-seroconverted young women have very 295 low incidence of mixed infection, yet that multiple gB genotypes are almost universally detectable 296 in chronically-HCMV infected individuals (22) . Altogether, these data favor a model that mixed 297 infections in healthy individuals result from independent, sequential infection events.
298
Throughout the study, we identified several indications of vaccine-mediated effects on the 299 viral population. First, peak HCMV shedding in saliva was reduced by an order of magnitude in 300 gB/MF59 vaccinees compared to placebo, though no difference was observed for peak systemic 301 viral load or peak viral shedding in urine and vaginal fluid. This finding suggests that gB-elicited 302 antibodies may have limited viral replication in salivary glands. gB/MF59 vaccination is known to 303 elicit high titers of gB-specific IgG, IgA, and SIgA in parotid saliva (27) , which may have 304 suppressed HCMV salivary replication and reduced saliva viral shedding. Furthermore, we 305 observed a trend towards reduced viral load in vaccinees when considering samples from all timepoints or those solely from the timepoint of seroconversion, though these comparisons were Indeed, our observation that gB5 genotype viruses were associated with increased viral load 311 further suggests that host response may have a lesser impact on viral replication during acute 312 infection than strain identity and viral pathogenicity.
313
The second identified impact of vaccination on the viral population was anatomic 314 compartmentalization. We found that 3 of 4 gB vaccinees with viral DNA available from multiple 315 compartments exhibited evidence of viral genetic compartmentalization at the gB locus, in 316 contrast to only 1 of 7 placebo recipients. As has been previously described (10) , we observed 317 that the dominant viral haplotype was identical between anatomic compartments in the majority 318 of subjects. The evaluation of gB-specific compartmentalization was therefore only possible 319 because of the ability of Short NGS Amplicon Population Profiling (SNAPP) to detect minor viral 320 variants in clinical samples. Our data are consistent with HCMV whole-genome NGS indicating 321 tissue-specific variants with intrahost variable SNPs present at relatively low frequency (11, 12) .
322
The mechanism leading to compartmentalization in vaccinees is unclear, though it is possible this 323 phenomenon stems from either neutral or positive selection in distinct anatomic compartments.
324
One hypothesis is that systemic gB-specific antibodies restricted free dissemination of HCMV 325 variants between tissue compartments. Such a bottleneck might have reduced founder population 326 size and increased the speed and likelihood of stochastic fixation of neutral SNPs and formation 327 of genetically-distinct viral populations (28, 29) . Alternatively, it is possible that local factors 328 including cell type and local antibody production/secretion at the site of HCMV replication selected 329 for "more fit" viral variants in each compartment.
Lastly, we observed an interesting trend that gB/MF59 vaccine recipients had reduced considering the genotypes identified by full gB ORF NGS, though not significant when considering viruses with genetic/antigenic similarity to the vaccine strain. Complementarily, we have observed 337 in the same gB/MF59 vaccinee cohort that gB-elicited neutralization activity was increased 338 against the autologous Towne strain virus, but not heterologous viruses AD169 and TB40/E (8) .
339
These observations raise the possibility that gB/MF59 vaccine-elicited protection against HCMV 340 acquisition had a limited antigenic scope. As demonstrated by force-of-infection modeling, 341 gB1/2/4 supergroup-specific protection could partially explain the 50% vaccine efficacy observed 342 in this phase 2 clinical trial. The concept of neutralization breadth has not been explored 343 extensively for HCMV, though several studies have described strain-specific neutralization (30- were detectable in additional vaccinees by SNAPP (Table 1 ), suggesting there may not have been 346 a true barrier to gB1/2/4 acquisition but perhaps merely restricted gB1/2/4 virus replication.
347
Furthermore, since the sample size is not robust, it is possible that our observation may have 348 been the result of sampling bias.
349
Far and away the largest limitation of this study was sample availability. Unfortunately, the 350 scope of our investigation was restricted by: 1) the original sampling timeline employed during the 351 clinical trial, 2) the availability of clinical samples, and 3) the integrity of the DNA more than a 352 decade following DNA extraction. Additionally, as with any study based on PCR amplification and 353 DNA sequencing, there is a potential for primer bias, contamination, and background error to 354 obscure the results. We instituted several measures to increase data integrity. First, primers were 355 designed and validated to prevent amplification bias (23). Additionally, PCR, sequencing, and methodologies (SNAPP and full gB ORF NGS) by comparing observed gB genotypes with sequencing methodologies were identical for 88% of all samples. However, because of the 361 relatively small cohort size and potential for sequencing error, our observed trends certainly merit 362 further investigation.
363
Nonetheless, this investigation is the first to employ NGS of viral DNA from infected HCMV 364 vaccinee and placebo recipients in an attempt to characterize the viral determinants of HCMV 365 acquisition. Importantly, our data robustly support notions in the HCMV field that the in vivo viral 366 population has a level of genetic complexity that cannot be appreciated using conventional 367 sequencing methodologies (11) (12) (13) , though the biological relevance of this genetic diversity of a 151-bp region from the US17 gene (25, 34) . As previously reported, the limit of detection is peroxidase (HRP)-conjugated goat anti-human IgG (1:50,000 in HRP stabilizer, KPL) was used 406 as detection antibody, followed by development using TMB peroxidase substrate solution (TMB 407 2-Component Microwell Peroxidase Substrate Kit, KPL). Endpoints were calculated based on the 408 intersection between the straight line through the falling portion of the optical density-serum 409 dilution curve and the cut-off optical density below which sera were negative for antibodies to gB.
410
Neutralizing antibodies were measured using a plaque reduction assay with HCMV AD169 (ATCC 411 #CCL-171) and MRC-5 cells (ATCC #VR-538) in 24-well tissue culture plates. Duplicate two-fold 412 dilutions of sera were tested starting at 1:8. Plaque counts were performed after a 7-day 413 incubation and the highest serum dilution with ≥ 50% reduction in plaque count was considered 414 the endpoint titer.
416
Short NGS amplicon population profiling (SNAPP). Flow chart detailing the sequencing strategy 417 is shown in Figure S1 . Variable regions approximately 550 base-pairs in length within gB (UL55) 418 and UL130 were amplified in duplicate by a nested PCR using the primers denoted in Table S1 .
419
Overhang regions were conjugated to PCR2 primers for subsequent Illumina index primer 
436
Full glycoprotein B open reading frame PCR and sequencing. Flow chart denoting sequencing 437 strategy is shown in Figure S1 . The full gB open reading frame (ORF) was amplified by nested 438 PCR using the primers denoted in Table S1 . Template DNA extracted from primary fluids was Tables: Table 1 . Viral load distribution (log10 copies/ml) by vaccination status at time of seroconversion.
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Total # samples Log 10 mean VL Log 10 median VL Log 10 VL IQR Placebo (21 
